Nitrofurantoin Rph Pharma (Nitrofurantoin)

The drug is reduced by bacterial flavoprotein enzymes to reactive metabolites that bind bacterial DNA and proteins. This causes oxidative damage and blocks macromolecular synthesis, halting bacterial growth and leading to cell death, especially in common urinary pathogens such as Escherichia coli.

The appropriate dose of Nitrofurantoin is determined by the prescribing clinician based on the type and severity of infection, the patient’s renal function, age, and other clinical factors. Dosage regimens are individualized and should follow the prescriber’s instructions.

Nitrofurantoin’s pregnancy safety category is listed as unknown. It should only be used during pregnancy or while breastfeeding when the potential benefits outweigh any possible risks, and after a thorough discussion with a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with agents such as trimethoprim‑sulfamethoxazole or fosfomycin, Nitrofurantoin offers a narrow spectrum focused on common urinary pathogens and achieves high urinary concentrations. It is often chosen when resistance to broader‑spectrum agents is a concern, though it requires adequate renal function for optimal efficacy.

Nitrofurantoin tablets should be stored at room temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in damp or excessively hot environments.

The medication is taken orally, usually with a full glass of water. It can be taken with or without food, but some patients find taking it with meals reduces gastrointestinal upset. Tablets should be swallowed whole and not crushed or chewed unless specifically directed by a healthcare provider.

Serious adverse reactions include pulmonary toxicity (interstitial pneumonitis or fibrosis), hepatic injury (elevated enzymes or hepatitis), severe allergic responses such as Stevens‑Johnson syndrome, hemolytic anemia in patients with G6PD deficiency, and peripheral neuropathy. Prompt medical attention is required if any of these symptoms develop.

Nitrofurantoin should be avoided in patients with severe renal impairment (creatinine clearance < 60 mL/min), known hypersensitivity to nitrofurantoin or other nitrofuran compounds, G6PD deficiency, and in late‑term pregnancy unless clearly indicated. Clinicians should also exercise caution in elderly patients and those with pre‑existing lung or liver disease.